ArticleAnnals of hematology2026
Healthcare resource utilization analysis in newly diagnosed mantle cell lymphoma: resource alleviation with adoption of the TRIANGLE ibrutinib regimen without autologous stem cell transplantation.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For younger, fit patients with mantle cell lymphoma (MCL), first-line therapy includes high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). HDCT-ASCT demands considerable healthcare resources and costs and causes acute and long-term complications. The phase 3 TRIANGLE trial found clinically beneficial improvements in overall survival and safety when HDCT-ASCT was replaced with an ibrutinib regimen without ASCT. This study aimed to develop a comprehensive ASCT treatment clinical pathway model for patients newly diagnosed with MCL and assess the impact on hospitalization duration, healthcare resources, and cost. The clinical pathway was modeled using ClipMed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.